MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319726 | Name: Amitifadine free base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amitifadine, also known as DOV-21,947 or EB-1010, is an antidepressant drug candidate. It is a so-called triple reuptake inhibitor (TRI) or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). Amitifadine reduces nicotine self-administration in female rats. Amitifadine reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.

Chemical Structure

Amitifadine free base
Amitifadine free base
CAS#410074-73-6 (free base)

Theoretical Analysis

MedKoo Cat#: 319726

Name: Amitifadine free base

CAS#: 410074-73-6 (free base)

Chemical Formula: C11H11Cl2N

Exact Mass: 227.0269

Molecular Weight: 228.12

Elemental Analysis: C, 57.92; H, 4.86; Cl, 31.08; N, 6.14

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
410074-74-7 (HCl) 410074-73-6 (free base)
Synonym
DOV-21,947; DOV21,947; DOV 21,947; DOV-21947; DOV21947; DOV 21947; EB-1010; EB 1010; EB1010; Amitifadine
IUPAC/Chemical Name
(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
InChi Key
BSMNRYCSBFHEMQ-KCJUWKMLSA-N
InChi Code
InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m1/s1
SMILES Code
ClC1=CC=C([C@]23CNC[C@@]2([H])C3)C=C1Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 410074-73-6 (Amitifadine) 410074-74-7 (Amitifadine Hydrochloride)

Preparing Stock Solutions

The following data is based on the product molecular weight 228.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. Eur J Pharmacol. 2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041. Epub 2015 Jun 20. PubMed PMID: 26101069. 2: Miller LL, Leitl MD, Banks ML, Blough BE, Negus SS. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain. 2015 Jan;156(1):175-84. doi: 10.1016/j.pain.0000000000000018. PubMed PMID: 25599313; PubMed Central PMCID: PMC4351716. 3: Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine. Drug Metab Lett. 2013 Mar;7(1):23-33. PubMed PMID: 23826879. 4: Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June HL. Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology. Pharmacol Biochem Behav. 2012 Nov;103(1):111-8. PubMed PMID: 22884707; PubMed Central PMCID: PMC3537915. 5: Marks DM, Abramowitz JS, Spielmans GI. Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial". J Psychiatr Res. 2012 May;46(5):692-3; author reply 694-5. doi: 10.1016/j.jpsychires.2012.02.002. PubMed PMID: 22520251. 6: Golembiowska K, Kowalska M, Bymaster FP. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse. 2012 May;66(5):435-44. doi: 10.1002/syn.21531. Epub 2012 Feb 15. PubMed PMID: 22213370. 7: Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012 Jan;46(1):64-71. doi: 10.1016/j.jpsychires.2011.09.003. Epub 2011 Sep 16. PubMed PMID: 21925682. 1: Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. Eur J Pharmacol. 2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041. Epub 2015 Jun 20. PubMed PMID: 26101069. 2: Miller LL, Leitl MD, Banks ML, Blough BE, Negus SS. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain. 2015 Jan;156(1):175-84. doi: 10.1016/j.pain.0000000000000018. PubMed PMID: 25599313; PubMed Central PMCID: PMC4351716. 3: Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD. Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine. Drug Metab Lett. 2013 Mar;7(1):23-33. PubMed PMID: 23826879. 4: Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June HL. Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology. Pharmacol Biochem Behav. 2012 Nov;103(1):111-8. PubMed PMID: 22884707; PubMed Central PMCID: PMC3537915. 5: Marks DM, Abramowitz JS, Spielmans GI. Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial". J Psychiatr Res. 2012 May;46(5):692-3; author reply 694-5. doi: 10.1016/j.jpsychires.2012.02.002. PubMed PMID: 22520251. 6: Golembiowska K, Kowalska M, Bymaster FP. Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse. 2012 May;66(5):435-44. doi: 10.1002/syn.21531. Epub 2012 Feb 15. PubMed PMID: 22213370. 7: Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012 Jan;46(1):64-71. doi: 10.1016/j.jpsychires.2011.09.003. Epub 2011 Sep 16. PubMed PMID: 21925682.